Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Rapport Therapeutics, Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-10 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-10
Exact text from the filing
Proposal 2 - Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection of PwC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of Proposal 2 were as follows: For Against Abstain 44,255,547 57,445 19,919
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Rapport Therapeutics, Inc. shareholders approved Election of Class II directors: James Healy, M.D., Ph.D., Robert J. Perez, and Raymond Sanchez, M.D. at the 2026-06-10 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-10
Exact text from the filing
Proposal 1 - Election of Class I Director Nominees The Company’s stockholders approved the Class II director nominees recommended for election in Proposal 1 at the Annual Meeting. The results of Proposal 1 were as follows: Class II Director Nominee For Withheld Broker Non-Votes James Healy, M.D., Ph.D. 41,762,713 587,163 1,983,035 Robert J. Perez 37,592,089 4,757,787 1,983,035 Raymond Sanchez, M.D. 41,754,131 595,745 1,983,035
View on SEC.gov